Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 4/20 | 0.41 |
| ▸ | ACE | P12821 | 11/20 | 0.35 |
| ▸ | EGLN1 | Q9GZT9 | 2/20 | 0.33 |
| ▸ | HIF1AN | Q9NWT6 | 2/20 | 0.33 |
| ▸ | BBOX1 | O75936 | 1/20 | 0.33 |
| ▸ | ASPH | Q12797 | 1/20 | 0.33 |
| ▸ | KDM8 | Q8N371 | 1/20 | 0.33 |
| ▸ | MME | P08473 | 2/20 | 0.32 |
| ▸ | ENO1 | P06733 | 1/20 | 0.30 |
| ▸ | OGFOD1 | Q8N543 | 1/20 | 0.30 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.30 |
| ▸ | EGLN3 | Q9H6Z9 | 1/20 | 0.30 |
| ▸ | USP5 | P45974 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4966311 | 0.89 | DPP4 (0.41) | DPP4ACEENO1 | |
| SCHEMBL4966481 | 0.85 | DPP4 (0.39) | DPP4ENO1 | |
| SCHEMBL4968977 | 0.85 | DPP4 (0.39) | DPP4 | |
| SCHEMBL4964030 | 0.81 | DPP4 (0.42) | DPP4ENO1 | |
| SCHEMBL4963814 | 0.80 | DPP4 (0.39) | DPP4ACE | |
| SCHEMBL4964982 | 0.79 | DPP4 (0.44) | DPP4 | |
| SCHEMBL4971566 | 0.78 | DPP4 (0.42) | DPP4 | |
| SCHEMBL4965924 | 0.78 | DPP4 (0.42) | DPP4 | |
| SCHEMBL4965083 | 0.78 | DPP4 (0.42) | DPP4 | |
| SCHEMBL4967875 | 0.77 | DPP4 (0.38) | DPP4EGLN1HIF1ANBBOX1ASPH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1489088-B1 | NOVEL ALPHA-AMINO-N-(DIAMINOPHOSPHINYL)LACTAM DERIVATIVE | NIPPON KAYAKU KK (JP) | 2008-08-13 | — | — | EP | disclosed |
| US-7348318-B2 | α-Amino-N-(diaminophosphinyl)lactam derivatives | NIPPON KAYAKU KABUSHIKI KAISHA (JP) | 2008-03-25 | — | — | US | disclosed |
| US-20050164989-A1 | Novel $g(a)-amino-n-(diaminophosphinyl) lactam derivative | NIPPON KAYAKU KABUSHIKI KAISHA (JP) | 2005-07-28 | — | — | US | disclosed |
| EP-1489088-A1 | NOVEL ALPHA-AMINO-N-(DIAMINOPHOSPHINYL)LACTAM DERIVATIVE | Nippon Kayaku Kabushiki Kaisha (JP) | 2004-12-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050164989-A1 | Novel $g(a)-amino-n-(diaminophosphinyl) lactam derivative | DNPEP, PEPD, ANPEP | DPP4 8/4885ACE 63/4885EGLN1 1590/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.